Abstract
Originally, locus symbols (e.g., DYT1) were introduced to specify chromosomal regions that had been linked to a familial disorder with a yet unknown gene. Symbols were systematically assigned in a numerical series to designate mapped loci for a specific phenotype or group of phenotypes. Since the system of designating and using locus symbols was originally established, both our knowledge and our techniques of gene discovery have evolved substantially. The current system has problems that are sources of confusion, perpetuate misinformation, and misrepresent the system as a useful reference tool for a list of inherited disorders of a particular phenotypic class. These include erroneously assigned loci, duplicated loci, missing symbols, missing loci, unconfirmed loci in a consecutively numbered system, combining causative genes and risk factor genes in the same list, and discordance between phenotype and list assignment. In this article, we describe these problems and their impact, and propose solutions. The system could be significantly improved by creating distinct lists for clinical and research purposes, creating more informative locus symbols, distinguishing disease-causing mutations from risk factors, raising the threshold of evidence prior to assigning a locus symbol, paying strict attention to the predominant phenotype when assigning symbols lists, and having a formal system for reviewing and continually revising the list that includes input from both clinical and genetics experts.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Neurology |
| Jahrgang | 78 |
| Ausgabenummer | 13 |
| Seiten (von - bis) | 1016-1024 |
| Seitenumfang | 9 |
| ISSN | 0028-3878 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 27.03.2012 |
Fördermittel
Dr. Marras has served as a consultant for Solvay Pharmaceuticals, Inc. and has received research support from Merck Serono, the National Parkinson Foundation, Parkinson Study Group, Parkinson Disease Foundation, Michael J Fox Foundation, and the Canadian Institutes of Health Research. Dr. Lohmann received funding from the German research foundation and the Bachmann-Strauss dystonia and Parkinson foundation. Dr. Lang has served on scientific advisory boards for Abbott, Allon Therapeutics, Inc., Biovail Corporation, Boehringer Ingelheim, Cephalon, Inc., Ceregene, Eisai Inc., Medtronic, Inc. Lundbeck Inc., NeuroMolecular Pharmaceuticals, Novartis, Merck Serono, Solvay Pharmaceuticals, Inc., TaroPharma, and Teva Pharmaceutical Industries Ltd.; has received speaker honoraria from GlaxoSmithKline and UCB; receives/has received research support from the Canadian Institutes of Health Research, the Dystonia Medical Research Foundation, the Michael J Fox Foundation, the National Parkinson Foundation, and the Ontario Problem Gambling Research Centre; and has served as an expert witness in cases related to the welding industry. Dr. Klein has received speaker honoraria from GlaxoSmithKline, Boehringer Ingelheim, Merz Pharmaceuticals, LLC, and Orion Corporation; serves on the editorial boards of Neurology ®, Movement Disorders , and Parkinson's Disease ; serves as a consultant for Centogene, Boehringer Ingelheim, and Link Medicine; and receives research support from the German Research Foundation (DFG), intramural funding from the University of Lübeck, the Volkswagen Foundation, the Possehl Foundation, the Hermann and Lilly Schilling Foundation, and the Fritz Thyssen Foundation.
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
-
SDG 10 – Weniger Ungleichheiten
Fingerprint
Untersuchen Sie die Forschungsthemen von „Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver